The Warburg Pincus Integrace acquisition, announced on 15 July 2026, marks a 100% buyout of a leading domestic pharmaceutical formulations company by one of the world’s most established growth equity investors. As part of the transaction, existing shareholders True North and Temasek fully exited their investment in the company. Three top-tier Indian law firms — Cyril Amarchand Mangaldas, Khaitan & Co, and JSA Advocates & Solicitors — provided comprehensive legal counsel across the deal.
Introduction
Warburg Pincus announced the acquisition of Integrace Private Limited, a leading domestic formulations company focused on orthopedics and gynecology. True North and Temasek fully exited Integrace, where they jointly held a 99.74% stake. The transaction was structured as a 100% acquisition, with True North Fund VI LLP exiting via its fund vehicle and Temasek exiting through its special purpose vehicle, V-Sciences Investments Pte Ltd.
Integrace has built a differentiated portfolio of more than 20 brands across attractive high-growth markets and, through its scientific marketing practices, has built trusted relationships with over 45,000 healthcare professionals across India. The company’s core therapeutic focus spans orthopedics, pain management, pregnancy care, and women’s health, with five power brands ranking among the top three in their respective markets.
Legal Teams Involved
Three law firms advised the respective parties across a broad range of practice areas, deploying some of their most senior cross-disciplinary talent.
Cyril Amarchand Mangaldas — Advised Warburg Pincus
Cyril Amarchand Mangaldas advised Warburg Pincus on the acquisition of Integrace Private Limited. The firm deployed multiple specialist teams covering transaction structuring, due diligence, regulatory advisory, intellectual property, pharmaceutical regulation, employment, ESOP, anti-bribery and competition law.
Strategic Guidance
- Reeba Chacko — Senior Partner
Transaction Team
- Vandana Sekhri — Partner (team lead)
- Siddharth Vedula — Partner
- Dhrumil Sanghvi — Principal Associate
- Ayushi Jhawar — Associate
Due Diligence Team
- Vandana Sekhri — Partner (team lead)
- Arun Prabhu — Partner – Co-Head – Digital | TMT (team lead)
- Siddharth Vedula — Partner
- Dhrumil Sanghvi — Principal Associate
- Ayushi Jhawar — Associate
Regulatory Advisory Team
- Vandana Sekhri — Partner (team lead)
- Arun Prabhu — Partner – Co-Head – Digital | TMT (team lead)
- Subhankar Pasalapudi — Partner (team lead)
- Princy D’souza — Associate
Intellectual Property, Information Technology & Data Protection Team
- Arun Prabhu — Partner – Co-Head – Digital | TMT (team lead)
- Arpita Sengupta — Partner (team lead)
- Mansi Jain — Associate
- Princy D’souza — Associate
- Pooja Bommareddy — Associate
Pharmaceutical Regulatory Diligence & Advisory Team
- Arun Prabhu — Partner – Co-Head – Digital | TMT (team lead)
- Biplab Lenin — Partner (team lead)
- Anam Chowdhary — Associate
Employment Diligence & Advisory Team
- Krithika Radhakrishnan — Partner (team lead)
- Shivika Gupta — Senior Associate
ESOP Structuring & Transition Advisory Team
- Sindhushri Badarinath — Partner (team lead)
- Shubham Parkhi — Director – Corporate Practice
- Aarav Prasad — Associate
- Rashi Kabra — Associate
ABAC, AML & Sanctions Diligence & Advisory Team
- Sara Sundaram — Partner (team lead)
- Nikhil Kansal — Associate
- Irene Sarkar — Associate
Competition Law Advisory Team
- Avaantika Kakkar — Partner – Head – Competition (team lead)
- Anshul Jain — Senior Consultant
Khaitan & Co — Advised True North and Integrace
Khaitan & Co provided end-to-end legal support to True North and Integrace, encompassing legal vendor due diligence, structuring, transaction documentation, regulatory advice and closing support.
Transaction Team
- Niren Patel — Partner
- Saswat Subasit — Partner
- Ruturaj Jere — Principal Associate
- Akhil Kumar — Senior Associate
- Yash Dawda — Associate
Pharma Regulatory
- Sameer Sah — Partner
Transaction Documentation & Closing Support
- Ravali Rayaprolu — Principal Associate
- Priyal Reddy — Senior Associate
- Alankrita Singh — Senior Associate
- Sama Sushma Reddy — Senior Associate
- Shrishti Mishra — Senior Associate
- Tirthesh Jain — Associate
- Vinita Jagtiani — Associate
Vendor Due Diligence
- Anshul Prakash — Partner
- Abhimanyu Pal — Partner
- Sourav Dan — Counsel
- Kruthi Murthy — Principal Associate
- Shivani Devpura — Principal Associate
- Ajeta Anand — Senior Associate
- Toshika Soni — Associate
- Shouraseni Chakraborty — Associate
- Khushi Sharma — Consultant
JSA Advocates & Solicitors — Advised Temasek
JSA Advocates & Solicitors advised Temasek with respect to its investment in Integrace Private Limited. Further details of the JSA team were not disclosed.
Significance and Impact
The deal comes amid continued investor interest in India’s pharmaceutical sector, which has seen steady demand growth, with segments such as women’s health and orthopedics attracting attention from healthcare investors.
Warburg Pincus has been investing in India for three decades and, over time, has built one of the country’s most established healthcare investment franchises, partnering with leading businesses across pharmaceuticals, medical technology, healthcare services and life sciences. The Integrace acquisition adds a therapy-focused, brand-led domestic formulations platform to that portfolio.
The transaction is also notable for the scale and specialisation of legal advisory deployed. Cyril Amarchand Mangaldas fielded ten distinct practice teams — covering areas as varied as competition law, ABAC/AML sanctions diligence, ESOP structuring, and pharma regulatory — reflecting the layered complexity of a 100% PE buyout in the healthcare sector. Khaitan & Co’s simultaneous representation of both the selling fund and the target company, with a dedicated vendor due diligence workstream, further illustrates the transactional depth involved.
For True North and Temasek, the exit represents a full realisation of their investment made through True North Fund VI LLP and V-Sciences Investments Pte Ltd respectively. True North and Temasek jointly held a 99.74% stake in Integrace at the time of the transaction.
Track more high-value PE and M&A mandates on the Deal Meter.
The Warburg Pincus–Integrace transaction is a significant milestone in India’s specialty pharmaceuticals M&A landscape, combining a complete PE exit with a strategic buyout by one of the country’s most active healthcare investors. The acquisition underscores Warburg Pincus’ strategy of building scaled, therapy-focused pharmaceutical platforms in India, where rising healthcare awareness, increasing incomes, and expanding access to quality healthcare continue to drive long-term market growth. With three leading law firms deploying multi-practice teams across the transaction, this deal sets a benchmark for legal advisory depth in Indian healthcare M&A.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
